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A B S T R A C T
Background: Children with congenital CMV infection (cCMV) shed virus in urine and saliva for prolonged per-
iods of time. Outcome of cCMV varies from asymptomatic infection with no sequelae in most cases, to severe
longterm morbidity. The factors associated with asymptomatic cCMV are not well defined. We evaluated the
viral shedding in a cohort of infants with cCMV identified on newborn screening. In addition, we describe the
distribution of viral genotypes in our cohort of asymptomatic infants and previous cohorts of cCMV children in
the literature.
Methods: Study population consisted of 40 children with cCMV identified in screening of 19,868 infants, a
prevalence of 2/1000. The viral shedding was evaluated at 3 and 18 months of age by real-time CMV-PCR of
saliva and plasma, and CMV culture of urine. CMV positive saliva samples were analyzed for genotypes for CMV
envelope glycoproteins gB (UL55), and gH (UL75) by genotype specific real-time PCR, and gN (UL73) by cloning
and sequencing
Results: At 3 months age 40/40 saliva and urine samples, and 19/40 plasma samples were positive for CMV. At
18 months age all urine samples tested (33/33), 9/37 of saliva samples, and 2/34 plasma samples were positive
for CMV. The genotype distribution did not differ from the published data
Conclusions: The urinary virus shedding is more persistent than salivary shedding in children with cCMV. The
genotype distribution was similar to previous literature and does not explain the low disease burden of cCMV in
our population.
1. Background
Approximately 0.6 % of children in the developed countries acquire
congenital CMV infection (cCMV) during fetal life [1,2]. Most infants
with cCMV and those who acquire CMV infection early in life continue
to shed the virus in urine and saliva for prolonged periods of time [3].
Following primary CMV infection, virus shedding can be detected in-
termittently during periods of reactivations of the persistent infection or
infection with new virus trains (reinfections) [3,4].
CMV has extensive genetic diversity. Envelope glycoproteins have
an important role in host immune response and viral replication [5,6].
Variability in the genes encoding these proteins have been speculated to
contribute in the virulence of the strain.6] Glycoprotein B, the major
component of the lipid envelope, plays an important role in the virus
entry and cell-to-cell spreading. Glycoprotein H and its complexes with
other glycoproteins are involved in the fusion of the virus to the host
cell membranes, essential step for the viral entry into the cells. Glyco-
protein N is involved in the virus attachment to the host [5]. However,
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the current knowledge about the virulence factors among different
strains is incomplete.
In Finland the disease burden of cCMV has been low. The pre-
valence of cCMV was only 2 in 1000 [7]. Additionally, in all University
hospitals covering about 30 000 births per year, only 29 children with
symptomatic cCMV infection had been identified between 2000 and
2012 [8].
2. Objectives
The objective of our study was to describe the viral shedding pat-
terns during the first 18 months of life in Finnish children with cCMV,
identified on newborn screening. In addition, the distribution of
genomic variants of envelope glycoproteins of CMV, glycoprotein B (gB,
UL55), glycoprotein H (gH, UL75) and glycoprotein N (gN, UL73) in
saliva samples from infected infants was examined and compared to
other cohorts in the literature. We also evaluated the association of
genotypes and viral excretion in the outcome of cCMV in our cohort.
3. Study design
The study population consisted of 40 children with cCMV identified
on screening of 19,868 infants born in Helsinki area Hospitals from
September 2012 to January 2015. The findings from the screening
study has been described earlier [7]. Informed consent was obtained
from the parents for the enrollment in the screening. Newborn CMV
screening was carried out by testing of saliva samples obtained during
the first week of life using a real-time PCR assay as described [7,9]. The
follow-up saliva, urine, and plasma samples were collected at 3 months
and at 18 months age. CMV shedding in the follow-up saliva samples
was determined using the same real-time CMV PCR assay [9]. The
saliva CMV-PCR was considered positive if one or more genomic
equivalents of CMV DNA per reaction were detected. The limit of de-
tection for genotyping PCR assay is 200 ge/ml. The plasma samples
were tested by a commercial assay (COBAS AmpliPrep/COBAS Taqman
CMV test, Roche) according to the manufacturer´s instructions to de-
termine viral load. The analytical sensitivity of the commercial assay is
56 IU/ml and linear range 137 IU/ml – 9.1 E 6 IU/ml. Urine samples
were tested by a rapid culture method to detect the presence of early
CMV nuclear antigen by immunofluorescence test, ≥1 cell showing a
typical positive nuclear signal was considered a positive finding [10].
The serial saliva samples from children with cCMV collected during
the first week of life, 3 months age, and 18 months age that were po-
sitive for CMV DNA were analyzed for genotypes of envelope glyco-
proteins, gB (UL55) and gH (UL75) using a genotype-specific real-time
PCR as previously described [11–14]. The screening saliva samples
were also examined to determine gN (UL73) genotypes by cloning of
the amplified gN and screening colonies as previously described [15].
The neurologic outcome of the children at 18 months age was
evaluated by the Griffiths Developmental Scales and the hearing was
tested with transient evoked otoacoustic emission (tEOAE) and sound
field audiometry (SF) as described earlier [7].
Statistical analyses were performed with IBM SPSS Statistics 22.
Mann-Whitney U test was used to determine if the viral genotype, po-
sitive DNAemia at 3 months age, or persistent salivary excretion of CMV
at 18 months of age were associated with hearing and neurodevelop-
mental outcomes and to compare the viral loads between symptomatic
and asymptomatic children. The Fisher´s exact test was used to explore
the association of different genotypes with the symptomatic and
asymptomatic infections.
4. Results
Of the 40 infants with confirmed cCMV identified in a prospective
newborn CMV screening, 4 had symptomatic infection and the re-
maining 36 infants were asymptomatic. The results of the newborn
CMV screening and outcome have recently been reported [7]. One child
was classified as symptomatic due to microcephaly, and three due to
calcifications seen in the cerebral ultrasound. The outcome at 18
months age did not differ from that of the healthy controls [7].
4.1. Virus shedding
The saliva and urine samples collected at 3 months of age from all
40 infected infants were positive for CMV by real-time PCR and culture,
respectively. At 3 months of age, plasma samples from 19/40 (48 %)
were positive for CMV by PCR with a viral load between 56 and 753 IU/
ml. Urine samples were collected from 33/40 children at 18 months of
age and all of those were positive by culture. The saliva PCR was only
positive in 9/37 (24 %) samples collected at the 18-month visit. CMV
DNAemia was present in only 2/34 plasma samples collected at 18
months of age. Both positive plasma samples had CMV DNA level under
the linear range 137 IU/ml. All three sample types (saliva, urine, and
plasma) collected at both 3-month and 18-month visit from 32 children
were tested. Both children with positive plasma CMV PCR at 18 months
were positive for urine culture and the saliva sample from one infant
was also positive. Fig. 1.
The viral load in the screening saliva sample at birth, or viral load in
the saliva or plasma sample collected at the 3-month visit did not differ
significantly between symptomatic and asymptomatic children. The
Fig. 1. Viral excretion in urine, saliva, and plasma at 3 months and 18 months age.
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CMV DNAemia at 3 months age or persistent saliva CMV-PCR positivity
at 18 months age was not associated with neurodevelopmental per-
formance in the Griffiths Developmental Scales or hearing thresholds at
18 months age.
4.2. CMV envelope glycoprotein genotypes
Screening saliva samples (gH, gB, and gN): Of the screening saliva
samples collected from the 40 infants with confirmed cCMV during the
first week of life, 38 were available for genotyping. The gH (UL75)
genotyping was completed for 34 samples. Both gH1 and gH2 were
distributed equally, 18/34 for each genotype. Two screening samples
contained both gH1 and gH2 genotypes (6 %). The glycoprotein B (gB,
UL55) genotyping could be accomplished in 37 samples and all samples
contained a single gB genotype. The gB1 was the most common geno-
type (19/37, 51 %) followed by gB3 (9/37, 24 %), gB2 (7/37, 19 %),
and gB4 (2/37, 5%). Genotyping of glycoprotein N (gN, UL73) was
completed in 24 screening saliva samples. The most common genotype
was gN1 in 7/24 (29 %), followed by gN4c in 6/24 (25 %), gN3b in 5/
24 (21 %), gN4a in 3/24 (13 %), and gN3a and gN4b in 2/24 (8%)
samples. One sample had multiple gN genotypes, gN1 and gN4a (4%).
New gN mutations resulting in amino acid changes that have not been
previously described were observed in four specimens. A comparison of
the distribution of the gH, gB, and gN in our cohort and in other cohorts
reported in the literature is presented in Fig. 2 [14,16–37].
4.3. Analysis of follow-up saliva samples for gH and gB genotypes
Among the study children with genotyping results for gH and gB
genes in screening saliva samples, the follow-up samples collected at 3
months of age were analyzed for gH (29/34) and gB (34/37) genotypes.
The same gH and gB genotypes that were present in the screening
sample were observed in the 3-month sample in all cases. The two
samples that had both gH genotypes in the screening sample, only one
gH genotype (gH2) was detected in the three-month saliva sample.
Only 9/37 saliva samples collected at 18 months of age were posi-
tive for CMV and of those, genotyping could be completed for 5. In four
of the 5 samples, a different gH or gB genotype was present in the 18-
month sample compared to screening and 3-month samples. The five
children with genotyping results from all time points, screening, 3
month and 18 months, are presented in Table 1. The genotype remained
same in the screening and 3 months but changes in most cases by 18
months age.
The genotypes of envelope glycoproteins, gH, gB, and gN were as-
sociated with neither symptomatic infection nor neurodevelopmental
outcome as measured using Griffiths Mental Development Scales
General Quotient.
5. Discussion
We have characterized virus shedding, and the distribution of gen-
otypes of envelope glycoproteins gB, gH and gN in children with con-
genital CMV infection identified in a large prospective newborn CMV
screening study. At 18 months age all children had persistent virus
shedding in urine in contrast to only 24 % of saliva samples. The
genotype distribution in the screening saliva samples was similar to the
reports from other cohorts in the literature. Children with cCMV shed
virus for prolonged periods of time [3,38]. Consistent with previous
studies, we also observed that urinary virus shedding was more
common (33/33) than salivary shedding (9/37) at 18 months age
[3,4,39].
In our cohort of predominantly asymptomatic infants, about half of
the infected infants (19/40, 48 %) were viremic at 3 months of age. The
finding is similar to that reported by Forner et al. who observed CMV
DNAemia at 3 months age in 50 % of 33 children with asymptomatic
cCMV born following maternal primary infection during pregnancy
[40]. Ten of 33 children (30 %) in that study developed long-term se-
quelae such as SNHL, hemiparesis, or intellectual impairment [40]. This
is in contrast to findings in our cohort demonstrating favorable outcome
at 18 months age [7]. The significance of DNAemia at 3 months of age
with respect to long-term outcome is not known. Some studies have
reported that higher viral loads are associated with long-term sequelae
[3,41] but other studies did not find this association [42]. In our cohort,
viremia at 3 months age was not associated with lower performance in
Griffiths Mental development testing at 18 months age. The viral loads
in plasma measured at 3 months age were low in all positive cases
(≤753 IU/ml).
Young children shedding the virus after congenital or postnatal in-
fection are considered the most important source of infection to preg-
nant women [43]. Our finding that less than a third of children with
cCMV continue to shed virus in saliva at 18 months is reassuring and
this rate of salivary virus shedding is similar to the reported rates of
shedding in healthy children attending day care [44,45]. Our findings
suggest that children with cCMV infection should be treated as other
children using standard hygiene precautions.
The distribution of genotypes of CMV glycoproteins, gH, gB and gN
in cohorts of infants with cCMV reported in literature and observed in
our study was shown in Fig. 2. The gH genotype distribution appears to
be similar in different geographic locations and populations
[14,16–18,36]. Both gH1 and gH2 genotypes seems to be equally dis-
tributed in the cohorts from USA, Poland, Austria, the Netherlands, and
in Pakistan.16–18,36] The genotype distribution was similar in dif-
ferent populations regardless whether the cohort consisted mainly of
asymptomatic (Finland and USA) or symptomatic infants (Poland)
[14,16].
However, the distribution of gB and gN genotypes showed more
variation between populations [14,17–27,29,31,32,34–37]. In our co-
hort, similar to most other studies, all four gB genotypes were present
with the dominance of gB1 in half of the samples [14,17–23,28,36]. In a
Brazilian cohort of 47 asymptomatic and 2 symptomatic infants, only
genotypes gB1-3 were present [33]. In cohorts from Poland, the geno-
type gB4 was missing in a cohort of 60 mainly symptomatic (72 %)
children and gB3 and gB4 were absent in a small cohort of 12 children
[19,21]. A Japanese cohort with 31 mostly asymptomatic children, had
only gB1 and gB3 genotypes. 23] In Mexico, samples from 5 children
with cCMV included only gB1 and gB2. 28] The CHIMES study in the
USA was the only study to report gB5 genotype [14].
The distribution of gN genotypes in infants with cCMV was de-
scribed in 7 published reports [14,18,29,31,32,34,37]. All 7 g N geno-
types were present with even distribution, except gN2 was absent in our
cohort, the Pakistani, and Brazilian cohort.18,29] The small cohort
from Brazil with 14 children lacked also gN3a and 3b genotypes.29] In
the Italian cohort from 2003, only four gN genotypes gN1, gN2, gN3,
and gN4 were reported. 34] However, gN genotyping data from our
study should be interpreted with caution because genotyping was only
completed for 24/40 infants.
Mixed infections were infrequent in our cohort. However, even
studies that observed higher rate of mixed infections did not find a
significant association between mixed infections and symptomatic in-
fection or sequelae [14]. The children in our cohort were mostly
asymptomatic and the outcome at 18 months was favourable [7]. The
number of infected infants and few children with mixed infection does
not allow us to make meaningful conclusions on the role of mixed in-
fections and outcome.
We observed same genotypes in samples collected at birth and at 3
months of age. However, in the small number of children in whom
genotyping was carried out in samples obtained at all three time points,
the 18-month sample contained a different genotype from the one seen
at birth and 3 months of age. It is possible for these children may have
been reinfected with a different strain from exposures in day care.
However, the small number of infants with data at all three time points
limits the utility of this finding.
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The strengths of our study are that we report the virus shedding and
genotyping data from an unselected cohort of children with cCMV
identified on screening. Most studies in the literature reporting
genotyping data present either children with symptomatic infection or a
smaller convenience sample of a larger cohort. A limitation of the study
is the small number of symptomatic children, only 4 children. It is
impossible to draw conclusions about the differences in genotypes or
viral shedding between symptomatic or asymptomatic children.
Another limitation is that the genotyping could not be performed for all
saliva samples.
In conclusion, the genotype distribution in our unselected popula-
tion-based cohort did not differ from the previously described cohorts.
Thus, the genotype distribution is unlikely to explain the relatively low
disease burden of cCMV reported in Finland [7,8]. Although all con-
genitally infected infants were shedding virus in the urine still at 18
months age, less than third of infected children were shedding the virus
in saliva.
Fig. 2. Distribution of the genotypes of envelope glycoproteins, gH (A), gB (B) and gN (C) in our cohort from Finland and in other cCMV populations in the literature.
*only gN4 reported instead of gN4a, gN4b, gN4c
Table 1
The gH and gB genotypes of the cases with genotyped CMV positive saliva
samples for all time points: screening, 3 months and 18 months.
case Screening saliva 3 month saliva 18 month saliva
1 gH2, gB3 gH2, gB3 gH1, gB4
2 gH1, gB2 gH1, gB2 gH1, gB no amp
3 gH2, gB2 gH2, gB2 gH1, gB no amp
4 gH2, gB1 gH2, gB1 gH no amp, gB4
5 gH1, gB2 gH1, gB2 gH1, gB3
no amp= could not be amplified.
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